Literature DB >> 1974339

[3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum.

Y Masuo1, D Pélaprat, D Scherman, W Rostène.   

Abstract

[3H]Dihydrotetrabenazine ([3H]TBZOH), a derivative of the monoamine depleting agent, tetrabenazine, has been shown to bind to the vesicular monoamine transporter. We studied the effect of unilateral nigral lesion with 6-hydroxydopamine on [3H]TBZOH binding in the striatum by means of quantitative autoradiography. Topographical analysis of striatal [3H]TBZOH binding showed in control rats a pattern similar to the known distribution of dopaminergic innervation, and allowed to visualize dopaminergic denervation in lesioned rats. A good correlation was found between striatal [3H]TBZOH binding levels and tyrosine hydroxylase activities in similar areas on adjacent slices following 6-OHDA lesions with varying severity. These data reveal that autoradiography of [3H]TBZOH binding is a good index for the visualization and quantitation of dopaminergic nerve terminals integrity in the striatum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974339     DOI: 10.1016/0304-3940(90)90426-a

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography.

Authors:  Elissa M Strome; Ivan L Cepeda; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

2.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

3.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

Review 4.  Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.

Authors:  Nicolaas I Bohnen; Kirk A Frey
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

5.  Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.

Authors:  Vesna Sossi; Katherine Dinelle; Michael Schulzer; Edwin Mak; Doris J Doudet; Raúl de la Fuente-Fernández
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-10       Impact factor: 9.236

Review 6.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

7.  Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.

Authors:  I Leroux-Nicollet; J Costentin
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

9.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

10.  Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Anna Lee; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  EJNMMI Res       Date:  2013-10-02       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.